As inherited muscular dystrophies such as DMD represent the most severe and irreversible conditions (here ignoring potential gene restoration therapies), it was considered that myostatin inhibition would show more promising results in milder phenotypes of the muscular disorder and conditions not arising from specific and inherited genetic malfunction. The gene discussed is MSTN; the disease is muscular dystrophy.